SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
GALT reported three months ended September 30, 2026 results. The price and volatility reaction is pending.
GALTearnings

Earnings reactions, page 2

Galectin Therapeutics, Inc. (GALT) FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $1.6 million for the quarter ended September 30, 2026, compared with $2.6 million for the same period in 2025.
  • General and administrative expenses were $1.8 million for the quarter ended September 30, 2026, compared to $1.6 million for the quarter ended September 30, 2025.
  • Net loss applicable to common stockholders was $3.6 million, or ($0.04) per share, for the quarter ended September 30, 2026.
  • The Company had $11.7 million of cash and cash equivalents as of September 30, 2026.
  • The Company eliminated approximately $105.8 million in total debt, consisting of $91.0 million in principal and $14.8 million in accrued interest, effective July 31, 2026.

Guidance

  • The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.

Notes

Richard E. Uihlein converted all outstanding principal and accrued interest under five of the Company’s line of credit facilities into 34,376,167 shares of common stock, effective July 31, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →